‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Executive Summary
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
You may also be interested in...
Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow
Allergan will spend 2018 trying to shift investor focus from the loss of Restasis patent exclusivity in the second half of the year to the company's R&D pipeline, including the late-stage "six stars" highlighted in 2017 and mid-stage programs that are moving into the spotlight.
Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Allergan's second quarter exceeded expectations and full-year guidance was raised slightly, but while the aesthetics business grew, ophthalmology with a 9.4% Restasis decline was a notable outlier.